EI

252.8

+0.12%↑

SAN

81.04

+0.07%↑

SHL.DE

46.45

+0.61%↑

PHIA

23.01

+0.97%↑

SRT3

181.2

+1.2%↑

EI

252.8

+0.12%↑

SAN

81.04

+0.07%↑

SHL.DE

46.45

+0.61%↑

PHIA

23.01

+0.97%↑

SRT3

181.2

+1.2%↑

EI

252.8

+0.12%↑

SAN

81.04

+0.07%↑

SHL.DE

46.45

+0.61%↑

PHIA

23.01

+0.97%↑

SRT3

181.2

+1.2%↑

EI

252.8

+0.12%↑

SAN

81.04

+0.07%↑

SHL.DE

46.45

+0.61%↑

PHIA

23.01

+0.97%↑

SRT3

181.2

+1.2%↑

EI

252.8

+0.12%↑

SAN

81.04

+0.07%↑

SHL.DE

46.45

+0.61%↑

PHIA

23.01

+0.97%↑

SRT3

181.2

+1.2%↑

Search

Argenx SE

Uždarymo kaina

SektoriusSveikatos priežiūra

570.4 -1.14

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

570.2

Max

571.4

Pagrindiniai rodikliai

By Trading Economics

Pajamos

76M

245M

Pardavimai

157M

948M

P/E

Sektoriaus vid.

35.277

34.393

Pelnas, tenkantis vienai akcijai

2.27

Pelno marža

25.883

Darbuotojai

1,599

EBITDA

37M

126M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

-2.07% downside

Dividendai

By Dow Jones

Kitas uždarbis

2025-10-30

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

5.2B

37B

Ankstesnė atidarymo kaina

571.54

Ankstesnė uždarymo kaina

570.4

Naujienos nuotaikos

By Acuity

38%

62%

121 / 374 reitingas Healthcare

Argenx SE Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-10 23:44; UTC

Karštos akcijos

Stocks to Watch: Jacobs Solutions, Argenx

2025-04-10 23:39; UTC

Pagrindinės rinkos jėgos

Argenx ADRs Gain, FDA Approves New Delivery Method of Existing Autoimmune Disease Treatment

2025-07-28 10:51; UTC

Rinkos pokalbiai

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

Akcijų palyginimas

Kainos pokytis

Argenx SE Prognozė

Kainos tikslas

By TipRanks

-2.07% į apačią

12 mėnesių prognozė

Vidutinis 438.33 EUR  -2.07%

Aukščiausias 545 EUR

Žemiausias 223 EUR

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Argenx SE kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

6 ratings

5

Pirkti

0

Laikyti

1

Parduoti

Rinkos nuotaikos

By Acuity

121 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.